Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Strategies for Implementing Cell-Free DNA Testing.

Howard Cuckle¹

¹Department of Obstetrics & Gynecology, Columbia University Medical Center, 622 West 168th Street, New York, NY 10032, USA.

Clinics in Laboratory Medicine

|May 29, 2016

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Third-Trimester Screening for Preeclampsia in Twins: Comparative Performance of Fetal Medicine Foundation Algorithm, Roche, and Quidel Triages.

Fetal diagnosis and therapy·2025

Same author

Evidence of reduced birthweight in Ukraine following the Russian invasion.

Scientific reports·2025

Same author

Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review.

Archives of gynecology and obstetrics·2025

Same author

Sequence of Events Leading to Medical Abortion for Fetal Indications after 34 Weeks' Gestation: 23 Years of Experience in a Single Medical Center.

Fetal diagnosis and therapy·2024

Same author

Validation of urinary Congo Red preeclampsia detection point-of-care devise.

Pregnancy hypertension·2024

Same author

Fetal magnetic resonance imaging in the confirmation of congenital anomalies found on routine mid-trimester ultrasound.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia·2024

Maternal cell-free DNA (cfDNA) screening offers superior aneuploidy detection compared to traditional methods. The contingent cfDNA approach, targeting high-risk women, is the most preferred strategy for clinical implementation.

Area of Science:

Genetics and Genomics
Prenatal Diagnostics
Bioanalytical Chemistry

Background:

Conventional multi-marker screening tests for fetal aneuploidy have limitations in discriminatory power.
Maternal plasma cell-free DNA (cfDNA) testing demonstrates significantly higher accuracy for detecting chromosomal abnormalities.
Implementing cfDNA screening into clinical practice requires strategic planning for optimal cost-effectiveness and detection rates.

Purpose of the Study:

To evaluate different strategies for integrating maternal plasma cfDNA testing into clinical prenatal screening protocols.
To compare the cost-effectiveness and diagnostic performance of primary, secondary, and contingent cfDNA screening approaches.
To identify the most efficient and effective method for utilizing cfDNA testing in routine prenatal care.

Keywords:

Aneuploidy Maternal plasma Prenatal Screening cfDNA

More Related Videos

Rapid Characterization of Genetic Parts with Cell-Free Systems

Rapid Characterization of Genetic Parts with Cell-Free Systems

Published on: August 30, 2021

Cell-Free DNA Integrity Analysis in Urine Samples

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Mar 20, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Rapid Characterization of Genetic Parts with Cell-Free Systems

Rapid Characterization of Genetic Parts with Cell-Free Systems

Published on: August 30, 2021

Cell-Free DNA Integrity Analysis in Urine Samples

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Main Methods:

Analysis of various cfDNA implementation strategies: primary (standalone or with nuchal translucency), secondary (post-conventional screening), and contingent (risk-based selection).
Evaluation of discriminatory power, detection rates, and false-positive rates for each strategy.
Assessment of cost-effectiveness for third-party payers and impact on invasive prenatal diagnosis rates.

Main Results:

Maternal plasma cfDNA testing exhibits superior discriminatory power for aneuploidy compared to conventional multi-marker screening.
Secondary cfDNA screening is cost-saving and reduces invasive procedures but may slightly decrease detection rates.
Primary cfDNA screening is currently not cost-effective for widespread adoption by third-party payers.

Conclusions:

The contingent cfDNA screening strategy, focusing on approximately 20% of women identified as highest risk by conventional testing, is the preferred approach.
This contingent model balances high detection rates, cost-effectiveness, and minimizes unnecessary invasive diagnostic procedures.
Contingent cfDNA testing represents a practical and efficient integration of advanced molecular diagnostics into prenatal care.